Crossref
Amgen, Inc. v. Sanofi: The Enablement Requirement of Patent Law: A Bargain for the People Stands the Test of Time
Tulane Journal of Technology & Intellectual Property · 13.01.2025 · 26
DOI: 10.37381/c04h2v75 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tulane Journal of Technology & Intellectual Property, online erschienen am 13.01.2025. Verfasst von Jonathan Talos.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Talos, J. (2025). Amgen, Inc. v. Sanofi: The Enablement Requirement of Patent Law: A Bargain for the People Stands the Test of Time. Tulane Journal of Technology & Intellectual Property, 26. https://doi.org/10.37381/c04h2v75
Vancouver
Talos J. Amgen, Inc. v. Sanofi: The Enablement Requirement of Patent Law: A Bargain for the People Stands the Test of Time. Tulane Journal of Technology & Intellectual Property. 2025;26. doi:10.37381/c04h2v75
BibTeX
@article{Talos2025,
author = {Talos, Jonathan},
title = {Amgen, Inc. v. Sanofi: The Enablement Requirement of Patent Law: A Bargain for the People Stands the Test of Time},
journal = {Tulane Journal of Technology & Intellectual Property},
year = {2025},
volume = {26},
doi = {10.37381/c04h2v75}
}
EUVIMED